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Mice were orally vaccinated with liposomes coated with filamentous hemagglutinin (FHA) and detoxified
pertussis toxin (PT) of BordeteUla pertussis. FHA- and PT-specific immunoglobulin G (IgG) was detected in
serum, and both IgG and IgA were detected in lung washes following the immunization. Antibody responses
in mice immunized with liposomes coated with FHA and PT were significantly higher than those in mice
immunized with free FHA and PT, which demonstrated the adjuvanticity of the liposome carrier. The results
indicate the potential usefulness of this approach for eliciting immune responses against FHA and PT (and
perhaps other pertussis antigens) in humans and its possible utility in large-scale vaccination to protect against
both B. pertussis infection and disease.
Bordetella pertussis is the etiological agent of whooping
cough, an infection of the human respiratory tract. The
disease is particularly severe in young children and may lead
to neurological disorders and death (48). The impact of
pertussis morbidity and mortality on health is usually under-
estimated because of underreporting; however, 60,000,000
cases and more than 500,000 deaths per year are estimated to
have a pertussis etiology or to be pertussis related (30). The
prevalence of pertussis in countries where vaccination is not
mandatory is very high, with 95% of the sera of 17- to
19-year-old individuals containing antibodies against pertus-
sis (16).
In developed countries, the incidence of whooping cough
has been reduced largely by mass immunization with a
heat-killed whole-cell vaccine (10). The benefits associated
with this vaccine clearly outweigh the risks of rare but
severe adverse effects, but nevertheless, public concern
about safety and immunogenicity has resulted in decreased
vaccination rates (22, 29). Moreover, the efficacy of the
whole-cell vaccine has been questioned in a few countries
such as the United States because, although immunization
rates are high, between 30,000 and 125,000 cases of pertussis
have occurred annually (43). Therefore, a new generation of
nontoxic and highly immunogenic vaccines, consisting of
well-defined components, is urgently needed. Several viru-
lence factors of B. pertussis have been considered for
inclusion in defined acellular vaccines, and detoxified per-
tussis toxin (PT) and filamentous hemagglutinin (FHA) are
prime candidates (27, 34). Conventional vaccines adminis-
tered by the parenteral route seem to primarily elicit humoral
immunity, and the secretory antibody responses are poor
(17, 41, 44). B. pertussis bacteria, however, infect the body
through the respiratory tract mucosal membrane, and spe-
cific immunoglobulin A (IgA) is elicited after natural infec-
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tion (44). Such antibodies may well protect the host from
both colonization and disease. It would, thus, seem worth-
while to explore means of stimulating mucosal immunity of
airways and to evaluate its utility in protecting from infection
and disease.
Liposomes have been successfully used as delivery sys-
tems for drugs, antigens, hormones, and genetic material
(18). Promising results have also been obtained following
immunization with liposome-associated antigens; the oral (3,
19, 35, 37, 47) and parenteral (4, 8, 13, 24, 25, 38, 39, 42)
routes have been used for antigens of parasites (4, 24, 25, 37,
39), viruses (13, 32), and bacteria (3, 8, 19, 35, 38, 42, 47).
Their potential as adjuvants has been demonstrated in sev-
eral studies, in which the use of liposome-associated anti-
gens resulted in protective immunity (4, 8, 19, 24, 25, 37, 39,
42) or at least cell-mediated (8) and humoral responses (3, 13,
38). The adjuvanticity of liposomes seems to depend on
several factors including vesicle size and structure, lipid
constitution, surface charge, antigen localization, the animal
species immunized, route of immunization, and the distribu-
tion and number of lamellae. The association of orally
administered antigens with liposomes enhances their absorp-
tion, targeting them to processing cells, and favors their
presentation to T cells and uptake into regional lymph nodes.
This process improves the induction of humoral, secretory,
and cell-mediated immune responses (1, 2, 18, 45).
In the present report, we describe the ability of FHA- and
PT-coated liposomes to induce specific systemic or secre-
tory immune responses following oral immunization of mice.
MATERIALS AND METHODS
Preparation of antigen-coated liposomes. FHA was purified
from B. pertussis Tohama as previously described by Sato et
al. (40), and PT was kindly supplied by S. Cryz (Swiss Serum
and Vaccine Institute, Berne, Switzerland) and detoxified as
described by Munoz et al. (31). Lyphazome liposomes, a
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commercial form of small multilamellar phospholipid vesi-
cles, containing B. pertussis FHA and PT, were prepared by
the solvent dilution microcarrier technique developed by
Fountain Pharmaceuticals, Inc. (11), using purified soybean
phosphatides supplied by American Lecithin Company,
New York, N.Y. The composition of the purified lipid
mixture was phosphatidylcholine, phosphatidylethanol-
amine, phosphatidic acid, and neutral lipids at an approxi-
mate ratio of 8:1:0.7:0.3. The unincorporated antigen was
removed by size exclusion chromatography. The final-prep-
aration vaccine was passed over a column whose gel matrix
was Sephadex G-25 medium. The coated liposomes were
excluded from the gel bed and ran in the excluded volume,
while the nonincorporated antigen was retarded and was
retained in the included volume. The presence of liposomes
and antigen was measured by turbulometric measurements
on collected fractions as previously described (12).
Size determinations of liposomes. Size analysis studies of
the FHA-coated and PT-coated liposomes were performed
immediately after synthesis by using a Coulter submicron
particle analyzer N4MD (Coulter Electronics, Inc., Hialeah,
Fla.).
Western blot analysis. Monoclonal antibody P12H3 against
FHA (14) and a cocktail of monoclonal antibodies reactive
against PT subunits S1 (E19), S4-S5 doublet (E205), and S2
and S3 (E251) (51) were used in Western blotting (immuno-
blotting) experiments (5). Free antigens and FHA-coated
and PT-coated liposomes were mixed with loading buffer at
a ratio of 1:1, and protein was electrophoresed according to
the procedure of Laemmli (28) using a 3.85% acrylamide
stacking gel and a 10% acrylamide separating gel. Proteins
were transferred to a nitrocellulose membrane (Bio-Rad
Laboratories SRL, MI, Segrate, Italy) with a semidry trans-
fer cell (Bio-Rad) by using 25 mM Tris-192mM glycine-20%
methanol (pH 8.3) as the transfer buffer and a 10% solution
of low-fat (0.3%) milk in phosphate-buffered saline (PBS)
(137 mM NaCl, 27 mM KCl, 14 mM Na2HPO4 2H20, 15
mM KH2PO4), pH 7.4, as the blocking reagent. The blocked
membrane was incubated for 2 h with the first antibody,
either P12H3 or a cocktail of E19, E205, and E251 hybri-
doma supernatant fluids diluted 1:20 in PBS (pH 7.4). After
three washes with PBS, the membranes were incubated for 1
h with horseradish peroxidase-conjugated goat anti-mouse
IgG diluted 1:500 in PBS (Southern Biotechnology Associ-
ates, Inc., Birmingham, Ala.). Membranes were washed and
developed by using 4-chloro-1-naphthol as a substrate. Pre-
stained molecular weight markers were purchased from
Bio-Rad.
Electron microscopy. Uncoated, FHA-coated, and PT-
coated liposomes were negatively stained with 4% aqueous
uranyl acetate, pH 4.5, according to the method of Valentine
et al. (46). For metal shadowing, the liposome samples were
absorbed onto freshly prepared collodium-covered 300-mesh
nickel grids, washed with distilled water, air dried, and
unidirectionally metal shadowed with platinum at an angle of
15°.
For immunoelectron microscopy, uncoated or antigen-
coated liposomes were absorbed onto freshly prepared col-
lodium-covered 300-mesh nickel grids and carefully washed
with distilled water. After being air dried at room tempera-
ture, the grids were treated with protein A-purified anti-FHA
or anti-PT polyclonal (21, 50) or monoclonal (14, 51) anti-
bodies (125 jig of IgG protein ml-') for 60 min at room
temperature. Unbound antibodies were removed by a mild
spray of PBS (pH 6.9) from a plastic bottle. The bound
antibodies were made visible for electron microscopy by
incubating the grids on drops of protein A-gold complexes
(gold particle size = 10 nm, A520 = 0.01) for 15 min at room
temperature. Subsequently, the grids were rinsed with PBS
containing 0.01% Tween 20 and then with distilled water.
After being air dried, the grids were unidirectionally metal
shadowed with platinum (angle, 150) or examined without
metal shadowing. In control experiments, the samples were
either treated with purified preimmune serum or with protein
A-gold complexes alone. For postembedding labeling, the
PT-coated liposomes were embedded according to the
method of progressive lowering of temperature by using
Lowicryl K4M resin and applying the labeling protocol as
described elsewhere (50). Samples were examined with a
Zeiss electron microscope EM 10B at an acceleration volt-
age of 80 kV and at calibrated magnifications.
Mouse immunization. Five- to six-week-old female
BALB/c mice (Charles River) were orally immunized in
groups of five as follows: group a, FHA-coated liposomes;
group b, PT-coated liposomes; group c, FHA-coated and
PT-coated liposomes; group d, free FHA; group e, free PT;
group f, free FHA and PT; control group, uncoated lipo-
somes. The animals were caged separately. The vaccination
regimen was one dose of protein (4 ,g) on days 0 and 4,
followed by a booster of an identical dose on day 30. Mice
that had been deprived of water for 6 to 8 h were orally given
50 ,ul of vaccine diluted in PBS and an equal volume of 3%
sodium bicarbonate in PBS, pH 8.0, which was added
immediately before in order to neutralize gastric acidity. The
animals were anesthetized with ether and sacrificed by
cervical dislocation 10 days after the booster. The blood
samples were collected by cutting the brachial artery, and
the serum was separated and stored at -20°C. Lung wash
samples were collected by pertracheal cannulation and gen-
tle washing with 0.7 ml of ice-cold PBS containing 2 mM
phenylmethylsulfonyl fluoride as a protease inhibitor. About
0.5 ml of lung wash was recovered from each mouse,
centrifuged at 4°C at 10,000 x g for 5 min to remove debris,
and stored at -20°C.
Determination of specific antibodies against FEIA and PT.
For the determination of class-specific antibodies against
FHA and PT present in serum and lung washes, enzyme-
linked immunosorbent assays (ELISA) were performed as
follows. Nunc Maxisorp Immunomodule 96-well plates were
coated with FHA or PT diluted in 0.1 M NaHCO3 (pH 9.6) at
60 ng in 50 ,lI per well and incubated at 4°C overnight. The
wells were blocked with 100 ,u of 10% fetal calf serum
(ICN-Flow Biomedicals Societa per Azioni MI, Cassina de'
Pecchi, Italy) in PBS for 2 h at 37°C. Plates were subse-
quently washed three times with PBS, and a 100-,ul serum
sample diluted 1:50 or lung wash sample diluted 1:10 in 10%
fetal calf serum in PBS was added to each well. After 60 min
at 37°C, the plates were again washed, 100 pI of alkaline
phosphatase-conjugated goat anti-mouse antibodies for IgG,
IgM, or IgA heavy chains (Southern Biotechnology Associ-
ates, Inc.) diluted 1:500 in 10% fetal calf serum in PBS was
added to each well, and the mixtures were incubated for 2 h
at 37°C. The plates were again washed and then developed
by the addition of 100 pl of the substrate solution (10 mg of
p-nitrophenylphosphate disodium salt per ml in diethanola-
mine buffer, pH 9.8) per well. After 30 min at room temper-
ature, the reaction was stopped by the addition of 50 pI of 3.0
M NaOH, and the A405 was determined with a Titretek
Multiskan MCC microplate reader (ICN-Flow Biomedicals
Societa' per Azioni). All samples were processed simulta-
neously on the same day, each serum or lung wash sample
was individually assayed in duplicate, and uncoated-lipo-
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FIG. 1. Incorporation of FHA and PT into liposomes. Lane 1,
molecular mass stanaarfs,;Tane^2,-uAced lposomes; lane 3, free
FHA; lane 4, FHA-coated liposomes; lane 5, free PT; lane 6,
PT-coated liposomes. FHA and PT subunits are indicated on the
right, and the molecular masses of the standards in kilodaltons are
indicated on the left.
some-immunized mouse serum or lung wash samples were
used as blanks for the ELISA readings (nonspecific activity,
0.025). Results are expressed as mean values for each
immunization group; standard deviations represent varia-
tions between individual mouse samples in each group.
Titration assays of representative samples demonstrated that
theA405 values obtained for the single point dilutions chosen
fall on the linear part of a standard curve.
Statistical calculations. Antibody responses of mice immu-
nized with FHA- or PT-coated liposomes and those immu-
nized with free FHA or PT were analyzed for significance by
analysis of variance and Student's t test. Differences were
considered significant at P c 0.05.
RESULTS
Size determinations of liposomes containing FHA and PT.
The mean diameters (with 95% confidence intervals in
parentheses) of uncoated and FHA- and PT-coated lipo-
somes were 227 (211 to 243) nm, 236 (219 to 253) nm, and 244
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FIG. 2. Electron-microscopic examination of FHA-coated liposomes that were negatively stained (B), unidirectionally metal shadowed(C), incubated with polyclonal anti-FHA antibodies and then with protein A-gold complexes without (D) or with (E) metal shadow, or
incubated with preimmune serum and protein A-gold complexes (F). Negatively stained uncoated liposomes are shown in panel A. G, gold
particle. Bars, 0.2 .Lm.
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D
FIG. 3. Electron-microscopic examination of PT-coated liposomes that were negatively stained (A), incubated with polyclonal antibodies
against PT and then with protein A-gold complexes and metal shadowed (B), incubated with preimmune serum and then with protein A-gold
complexes and metal shadowed (control experiment) (C), or incubated with polyclonal anti-PT antibodies and protein A-gold complexes
(postembedding labeling) (D). G, gold particle. Bars, 0.1 p.m.
(226 to 262) nm, respectively. These data suggest that the
incorporation of FHA and PT into the liposomes does not
significantly affect the average diameter of the liposomes.
Western blot analysis of liposomes containing FHA and PT.
The presence of FHA and PT in the vesicles was confirmed
by Western blot analysis using the P12H3 monoclonal anti-
body (Fig. 1, lanes 2, 3, and 4) and the cocktail of hybridoma
supernatants against PT subunits Si to 4 (Fig. 1, lanes 2, 5,
and 6). No differences in FHA content between free FHA
and FHA-coated liposomes (Fig. 1, lanes 3 and 4) were
detected. On the other hand, differences between free PT
and liposome-incorporated PT were evident (Fig. 1, lanes 5
and 6), suggesting either variations in binding affinity be-
tween monoclonal antibodies specific for Si or S4 and S2 or
S3 or preferential incorporation of Si and S4-S5 subunits in
the liposomes. No proteins were detected in the uncoated
liposomes (Fig. 1, lane 2).
Immunoelectron-microscopic analysis of liposomes contain-
ing FHA and PT. Electron microscopy of the uncoated,
FHA-coated, and PT-coated liposomes revealed that the
liposomes were multilamellar and varied in size (Fig. 2A, B,
and C and 3A). The differences in size were greater than
those shown by Coulter analysis. This could be due in part to
either storage after synthesis or the methods used for elec-
tron microscopy. Moreover, the FHA- and PT-coated lipo-
somes exhibit a morphological appearance different from
that of the uncoated liposomes (compare Fig. 2A with B and
with 3A), with the presence of protrusions most probably
due to the incorporation of FHA and PT into the liposomes.
However, the protrusions are not artifacts, as demonstrated
by metal shadowing (Fig. 2C and E and 3B). Incubation of
the FHA-coated liposomes with anti-FHA polyclonal anti-
bodies and then with protein A-gold complexes resulted in
an intensive labeling pattern on the surface of the FHA-
coated liposomes (Fig. 2D and E). Incubation with the
monoclonal antibodies against FHA revealed less labeling
(data not shown). Incubation of the PT-coated liposomes
with polyclonal anti-PT antibodies resulted in a labeling
pattern much weaker than that for the FHA-coated lipo-
somes (compare Fig. 2D with 3B). Since the label intensity
was sometimes only slightly above the background level, we
have undertaken to demonstrate by postembedding labeling
that PT can be detected on the liposome membrane. The
former method allows only for the detection of antigenic
reactive sites which stick out of the liposomes but not of
those which reside on the inner side of the liposome mem-
brane. In Fig. 3D, a liposome which exhibits a label around
the membrane is depicted, demonstrating that PT is incor-
porated in the external membrane. In control experiments
(Fig. 2F and 3C), only a very few gold particles could be
detected.
Antibody responses specific for B. pertussis FHA and PT in
vaccinated mice. Both free FHA and PT and PT- and
FHA-coated liposome prototype vaccines elicited specific
serum and mucosal antibody responses (Fig. 4 and 5). After
oral immunization of mice with a total dose of 12 ,ug of FHA
or PT, administered in three equal doses, both systemic
(mainly IgG) and lung secretory (mainly IgG and IgA)
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FIG. 4. Levels of anti-FHA specific antibodies in serum (A) and
lung wash (B) samples after oral immunization of mice with free
FHA and FlIA-coated liposomes. Bars, standard deviations.
antibody responses were obtained (Fig. 4A and B). The
adjuvanticity of the liposome-based system was confirmed
for FHA by the presence of antibody responses in mice
immunized with FHA-coated liposomes that were approxi-
mately three times higher than the responses in mice immu-
nized orally with free protein (Fig. 4). The differences in
antibody levels between mice immunized with FHA-coated
liposomes and those immunized with free protein were
statistically significant (P c 0.05). Simultaneous vaccination
with FHA and PT, both free and liposome associated, did
not affect anti-FHA antibody responses. The levels of FHA-
specific IgM detected in lung wash samples were not signif-
icant (P > 0.05).
Similar results were obtained by immunization with PT
(Fig. 5A and B), and as with FHA, coimmunization with
both proteins (FHA and PT) gave good anti-PT antibody
responses.
DISCUSSION
Current parenteral vaccines against whooping cough are
more effective in protecting against clinical pertussis than
against infection. In designing new, safer vaccines, however,
it would seem appropriate to reconsider the immunization
strategy and to take into account the respiratory tract portal
of entry of pertussis infection and possible use of vaccines
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FIG. 5. Levels of anti-PT specific antibodies in serum (A) and
lung wash (B) samples after oral immunization of mice with free PT
and PT-coated liposomes. Bars, standard deviations.
that stimulate efficient responses at the mucosal level which
block infection. Secretory IgA and specific IgG (derived
from serum by transudation through capillary vessels and
being the predominant Ig in the lower respiratory tract) may
interfere with the early events of bacterial attachment and
colonization and thereby facilitate the eradication of the
disease.
The site of antigen processing influences the Ig class
profile of the immune response elicited. In fact, the secretory
IgA response is typical of antigen administration by oral
route (2, 6, 19, 23, 26, 45). The specialized M cells which
cover the Peyer's patches pass antigenic material to lympho-
cytes below the epithelium, where the processed antigens
are presented to IgA precursor B cells. These B cells travel
via the lymphatic system to the different mucosae and then
give rise to IgA-secreting plasma cells. T lymphocytes may
also acquire their homing pattern in the Peyer's patches (45).
B. pertussis whole-cell vaccine given orally was demon-
strated to be as effective as parenterally administered vac-
cine (9). We have recently demonstrated specific lung mu-
cosal responses against FHA and the S1 subunit of PT after
oral immunization with recombinant aroA mutants of Sal-
monella spp. (20, 49). The present work extends these
observations by demonstrating that systemic and mucosal
immune responses against B. pertussis antigens follow oral
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immunization with free FHA and PT. The incorporation of
FHA and PT into the liposome delivery system resulted in an
adjuvant effect with greatly improved antibody responses.
The immunizations were administered orally, mimicking the
method which could be used in human oral vaccines. There-
fore, we cannot rule out partial contributions to the elicited
immune responses from other mucosa-associated immune
tissues (i.e., nasal, salivary, and/or esophageal) in addition
to those of gut-associated tissues.
The liposome system can be used to deliver multiple
antigens including the 69-kDa outer membrane protein of B.
pertussis, which was recently demonstrated to be an impor-
tant protective antigen (33). Escherichia coli strains which
express recombinant FHA (21), Bordetella sp. strains which
overproduce PT (50, 52), and methods for the genetic
detoxification of PT (36, 52) are now available and will
facilitate the production of high yields of nontoxic, fully
antigenic components for liposome-based subunit vaccines.
In fact, multivalent vaccines which could replace the old
DTP vaccine in infant vaccination regimes can be envisaged,
as enhancement of the primary and secondary immune
responses has resulted from diphtheria toxoid association
with liposomes (1).
The mechanisms which mediate protection against B.
pertussis infection are not clearly understood. Humoral and
cellular responses following parenteral immunization do not
always correlate (36). Moreover, cell-mediated immune re-
sponses are believed to be important in vivo for protection
against whooping cough disease (7, 15). As liposomes are
known to induce cell-mediated immunity, it will be of
interest to determine whether the delivery systems used in
this study induce cell-mediated responses to FHA and PT in
addition to the documented antibody responses.
The immune responses elicited following immunization
with FHA- and PT-coated liposomes reported in this work
suggest the usefulness of this delivery system in the devel-
opment of oral vaccines against whooping cough. However,
the system could be further enhanced by the incorporation of
other products known to have adjuvant activity, which may
have additive or synergistic effects on secretory-IgA priming
(35, 38), and/or administration of vitamin A, which may
improve the immune responses after oral vaccination (2).
Moreover, other aspects, including the length of the immu-
nity obtained, optimal vaccination schedule, and protection
after challenge, must be investigated also.
The use of liposomes as a delivery system for subunit
vaccines to induce immune responses distal to the site of
entry are very promising. The oral route may reduce or
eliminate the most frequent local side effects associated with
whooping cough vaccines; then, adjuvanticity may increase
both cell-mediated and humoral immune responses. Lipo-
somes are chemically stable, simple to manufacture, and
biodegradable; toxicity was not reported after liposomes
were used in phase I and II trials (1, 18). Moreover, the
inexpensive raw materials used to produce the liposomes
will contribute to reduced production costs. The oral admin-
istration of vaccines is in any case associated with a major
cost saving vis-a-vis parenteral vaccination and is a key
aspect of major vaccination programs, particularly in rural
settings, where health care delivery is very expensive.
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